Ropeginterferon for myelodysplastic and myeloproliferative overlap conditions
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a medication called ropeginterferon alfa-2b for people with certain blood cancers that have features of both myelodysplastic syndromes and myeloproliferative neoplasms. The drug may help control blood counts and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with a type of MDS/MPN overlap (including CMML or related conditions).
- Your blood counts are in a certain range (platelets above 50,000, white blood cells above 1,000).
- You have not taken interferon or azacitidine before.
- You do not have active autoimmune disease, serious depression or anxiety, or severe eye problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
This Phase 2 trial studies ropeginterferon alfa-2b (a type of interferon medicine) in adults with early, lower-risk myelofibrosis. The goal is to see if it can control the disease better or improve outcomes with an acceptable safety profile.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This trial tests combining two drugs, ropeginterferon alfa-2b and azacitidine, for people with myelodysplastic syndrome or acute myeloid leukemia that has a TP53 gene change. The treatment may help control the cancer, and the study includes people who are newly diagnosed or whose disease has not responded to prior therapy.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
Hear when a new Atypical Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.